Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1/20 vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Prevention of pregnancy in women who elect to use an oral contraceptive
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
One tablet orally once daily for 28 consecutive days per cycle.
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Ethinyl estradiol is metabolized primarily via CYP3A4, with sulfation and glucuronidation. Norethindrone is reduced and conjugated, primarily via CYP3A4 and other CYP450 enzymes.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Ethinyl estradiol: 97-98% (albumin, SHBG); norethindrone: 80-85% (albumin, SHBG)
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 2.5-5 L/kg; norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: ~40% for ethinyl estradiol (first-pass metabolism); ~64% for norethindrone (range 50-75%)
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min) may require monitoring due to potential fluid retention; use lowest effective dose.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, use with caution and only if benefits outweigh risks; consider alternative methods of contraception. Child-Pugh class A: no adjustment necessary.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Approved for post-menarcheal adolescents. Same dosing as adults: one active tablet daily for 21 days, then placebo for 7 days. Weight-based adjustments not required.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Not indicated for postmenopausal women. No specific geriatric dose adjustments, but consider increased risk of thrombotic events and manage cardiovascular risk factors.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women >35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders: Risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction.,Hepatic disease: Discontinue if jaundice or cholestasis develops.,Hypertension: Monitor blood pressure; may cause new-onset or worsening hypertension.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate metabolism: May impair glucose tolerance.,Hypertriglyceridemia: May cause pancreatitis if elevated.,Uterine bleeding: Discontinue if unexplained amenorrhea or irregular bleeding persists.,Ocular disorders: Retinal thrombosis; discontinue if sudden partial or complete vision loss.,Depression: May recur or worsen.,Toxic shock syndrome: Associated with use of vaginal rings, but not specifically with this pill.
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Benign or malignant liver tumors (current or history),Active liver disease (e.g., acute hepatitis, decompensated cirrhosis),Hypersensitivity to any component of the product
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No significant food interactions. However, grapefruit juice may slightly increase ethinyl estradiol levels; avoid large amounts. The ferrous fumarate in placebo pills may cause gastrointestinal upset; take with food if needed.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of malformations but potential for adverse effects from progestational agents and estrogen. Risk of fetal genital abnormalities with prolonged exposure.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Contraindicated in breastfeeding. Small amounts of estrogen and progestin (norethindrone) pass into breast milk. M/P ratio: not established for this combination. May reduce milk production and quality. Use alternative contraception if breastfeeding.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Contraindicated in pregnancy; no dose adjustments recommended as use is prohibited. No pharmacokinetic studies during pregnancy due to contraindication.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LARIN FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg). It uses a 24/4 regimen with 24 active pills and 4 ferrous fumarate placebo pills. The iron supplements in the placebo pills help reduce the risk of iron deficiency anemia. Advise patients that spotting or breakthrough bleeding is common in the first few cycles. Monitor for hypertension, migraines, and thrombotic events. Smoking increases cardiovascular risk, especially in women over 35. LARIN FE 1/20 may decrease milk production in breastfeeding women.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one pill daily at the same time each day. Swallow the pill whole; do not crush or chew.,Start the pack on the first Sunday after your period starts (unless instructed otherwise).,Use backup contraception (like condoms) for the first 7 days if you start taking the pill for the first time.,If you miss a pill, refer to the package insert for instructions. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, and breakthrough bleeding. These often improve after a few months.,Contact your healthcare provider if you experience severe abdominal pain, chest pain, sudden shortness of breath, severe headaches, vision changes, or leg pain/swelling (possible blood clots).,Talk to your doctor before starting if you smoke, are over 35, have high blood pressure, migraines with aura, or a history of blood clots.,The iron pills (brown tablets) are not active birth control; they are taken during the fourth week to help prevent anemia.,Do not stop taking the pill without consulting your doctor.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1/20 vs DEMULEN 1/50-28, answered by our medical review team.
LARIN FE 1/20 is a Combination Oral Contraceptive that works by LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1/20 and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1/20 is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1/20 and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1/20 is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Seco. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.